

REVENIO

Revenio Group Corporation: Revenio Group's financial reporting and Annual General Meeting in 2021

Revenio Group Corporation, Stock Exchange Release, December 14, 2020 at 9:00

REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2021

Revenio Group Corporation will publish the following financial reports during 2021:

- Financial Statements bulletin in regard to 2020 on Thursday, February 11, 2021
- Interim Report 1-3/2021 on Friday, April 23, 2021
- Interim Report 1-6/2021 on Thursday, August 5, 2021
- Interim Report 1-9/2021 on Thursday, October 21, 2021

The financial statements bulletin, half-yearly report and interim reports will be published at approximately 9 am Finnish time on the above dates.

Annual Report 2020

The Annual Report for 2020 will be published on the Group's website www.revenio.fi during week 8 in 2021. The Annual Report includes the company's Financial Statements, the Report of the Board of Directors and the Auditor's Report. At the same time, the company will publish a Corporate Governance Statement and a Remuneration Report for 2020.

Annual General Meeting 2021

The Annual General Meeting is planned to be held on Wednesday, March 17, 2021. The Board of Directors will give later a separate notice of the Annual General Meeting.

A shareholder, who wishes to include an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 1, 2021. Such requests including the reasoning, or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.

Revenio Group Corporation

For further information, please contact:

Jouni Toijala, CEO, tel. +358 50 484 0085

jouni.toijala@revenio.fi

www.revenio.fi

REVENIO

The Revenio Group in brief

Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group comprises Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

In 2019, the Group's net sales totaled EUR 49,5 million, with its operating profit standing at 25,5%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Revenio Group's financial reporting and Annual General Meeting in 2021](#)